After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
Stocks Info
Protagonist Therapeutics Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. The current market capitalization of Protagonist Therapeutics Inc is $2.37B. A total of 1.55 million shares were traded on the day, compared to an average of 667.71K shares.
Insider Activity
Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, PTGX has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 0 BUYs and 0 SELLs from insiders. Insiders purchased 0 shares during that period but sold 0.
In the most recent transaction, PATEL DINESH V PH D sold 5,359 shares of PTGX for 38.18 per share on Feb 19 ’25. After the transaction, the President and CEO now owns 540,260 company shares. In a previous transaction on Nov 27 ’24, MOLINA ARTURO MD sold 26,000 shares at 44.70 per share. PTGX shares that Chief Medical Officer owns now total 46,444.
Among the insiders who sold shares, MOLINA ARTURO MD disposed of 5,529 shares on Nov 26 ’24 at a per-share price of $45.60. This resulted in the Chief Medical Officer holding 46,444 shares of PTGX after the transaction. In another insider transaction, Gupta Suneel sold 103,437 shares at $46.04 per share on Nov 25 ’24. Company shares held by the Chief Development Officer now total 256,174.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for PTGX in the last 3 months, the mean price target is $59.91 with high estimates of $73.00 and low estimates of $38.00. In terms of 52-week highs and lows, PTGX has a high of $48.89 and a low of $24.22.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. PTGX’s latest balance sheet shows that the firm has $326.90M in Cash & Short Term Investments as of fiscal 2021. There were $5.86M in debt and $44.02M in liabilities at the time. Its Book Value Per Share was $11.06, while its Total Shareholder’s Equity was $300.02M.
Analysts Opinion
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for PTGX is Buy with a score of 4.80.
